Tags: Financial Markets | Health Topics | Healthcare Reform | Trump Administration | drug | prices | hikes

Report: Median Jan. 1 Drug Price Hike About 5 Percent

two hundred dollar bills lay on a light brown table next to a pile of different types of pills
(Mikhail Sotnikov/Dreamstime)

Thursday, 02 January 2020 07:23 PM

Drugmakers' price hikes in the U.S. on more than 250 drugs went into effect on the first day of the new year — and though nearly all were below 10%, the median is about 5%, Business Insider reported.

Bristol-Myers, which told BI it would not raise list prices on its drugs by more than 6% this year, raised the price on 10 drugs on Wednesday, including 1.5% price hikes on the cancer-immunotherapies Opdivo and Yervoy, and a 6% increase on its blood thinner Eliquis, all of which bring in billions in revenue every year, the news outlet noted.

It also raised the price on Celgene's flagship multiple-myeloma drug, Revlimid, by 6%. Bristol acquired its rival Celgene in a $74 billion deal last year, BI reported.

Gilead raised prices on more than 15 drugs including the HIV treatments Biktarvy and Truvada less than 5%, BI reported.

And Biogen price increases included a 6% price hike on the multiple-sclerosis treatment Tecfidera.

© 2020 Newsmax. All rights reserved.

   
1Like our page
2Share
Newsfront
Drugmakers' median price hike in the U.S. on more than 250 drugs went into effect on the first day of the new year is about 5%, and nearly all were below 10%, Business Insider reported.
drug, prices, hikes, big pharma, drugmakers
158
2020-23-02
Thursday, 02 January 2020 07:23 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved